Meningococcal Vaccines Market Size, Share & Trends Report

Meningococcal Vaccines Market Size, Share & Trends Analysis Report By Brand (Menactra, Menveo), By Type, By Serotype, By Age Group, By Sales Channel, By Region, And Segment Forecasts, 2023 - 2030

  • Report ID: GVR-4-68039-045-9
  • Number of Pages: 163
  • Format: Electronic (PDF)
  • Historical Range: 2018 - 2021
  • Industry: Healthcare

Market segmentation

  • Meningococcal Vaccines Market Type Outlook (Revenue, USD Million; 2018 - 2030)
    • Bivalent
    • Quadrivalent
    • Others
  • Meningococcal Vaccines Market Brand Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands))
    • Menactra
    • Menveo
    • Nimenrix
    • Trumenba
    • Bexsero
    • Others
  • Meningococcal Vaccines Market Age Group Outlook (Revenue, USD Million; 2018 - 2030)
    • Infants (0 to 2 years)
    • Children and Adults (2 years & above)
  • Meningococcal Vaccines Market Serotype (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands))
    • Serotype A
    • Serotype B
    • Serotype C
    • Serotype W-135
    • Serotype Y
  • Meningococcal Vaccines Market Sales Channel Outlook (Revenue, USD Million; 2018 - 2030)
    • Private
    • Public
  • Meningococcal Vaccines Market Regional Outlook (Revenue, USD Million; 2018 - 2030)
    • North America
      • North America Type Outlook (Revenue, USD Million; 2018 - 2030)
        • Bivalent
        • Quadrivalent
        • Others
      • North America Brand Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands))
        • Menactra
        • Menveo
        • Nimenrix
        • Trumenba
        • Bexsero
        • Others
      • North America Age Group Outlook (Revenue, USD Million; 2018 - 2030)
        • Infants (0 to 2 years)
        • Children and Adults (2 years & above)
      • North America Serotype Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
        • Serotype A
        • Serotype B
        • Serotype C
        • Serotype W-135
        • Serotype Y
      • North America Sales Outlook (Revenue, USD Million; 2018 - 2030)
        • Private
        • Public
      • U.S.
        • U.S. Type Outlook (Revenue, USD Million; 2018 - 2030)
          • Bivalent
          • Quadrivalent
          • Others
        • U.S. Brand Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands))
          • Menactra
          • Menveo
          • Nimenrix
          • Trumenba
          • Bexsero
          • Others
        • U.S. Age Group Outlook (Revenue, USD Million; 2018 - 2030)
          • Infants (0 to 2 years)
          • Children and Adults (2 years & above)
        • U.S. Serotype Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Serotype A
          • Serotype B
          • Serotype C
          • Serotype W-135
          • Serotype Y
        • U.S. Sales Outlook (Revenue, USD Million; 2018 - 2030)
          • Private
          • Public
      • Canada
        • Canada Type Outlook (Revenue, USD Million; 2018 - 2030)
          • Bivalent
          • Quadrivalent
          • Others
        • Canada Brand Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands))
          • Menactra
          • Menveo
          • Nimenrix
          • Trumenba
          • Bexsero
          • Others
        • Canada Age Group Outlook (Revenue, USD Million; 2018 - 2030)
          • Infants (0 to 2 years)
          • Children and Adults (2 years & above)
        • Canada Serotype Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Serotype A
          • Serotype B
          • Serotype C
          • Serotype W-135
          • Serotype Y
        • Canada Sales Outlook (Revenue, USD Million; 2018 - 2030)
          • Private
          • Public
    • Europe
      • Europe Type Outlook (Revenue, USD Million; 2018 - 2030)
        • Bivalent
        • Quadrivalent
        • Others
      • Europe Brand Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands))
        • Menactra
        • Menveo
        • Nimenrix
        • Trumenba
        • Bexsero
        • Others
      • Europe Age Group Outlook (Revenue, USD Million; 2018 - 2030)
        • Infants (0 to 2 years)
        • Children and Adults (2 years & above)
      • Europe Serotype Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
        • Serotype A
        • Serotype B
        • Serotype C
        • Serotype W-135
        • Serotype Y
      • Europe Sales Outlook (Revenue, USD Million; 2018 - 2030)
        • Private
        • Public
      • U.K.
        • U.K. Type Outlook (Revenue, USD Million; 2018 - 2030)
          • Bivalent
          • Quadrivalent
          • Others
        • U.K. Brand Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands))
          • Menactra
          • Menveo
          • Nimenrix
          • Trumenba
          • Bexsero
          • Others
        • U.K. Age Group Outlook (Revenue, USD Million; 2018 - 2030)
          • Infants (0 to 2 years)
          • Children and Adults (2 years & above)
        • U.K. Serotype Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Serotype A
          • Serotype B
          • Serotype C
          • Serotype W-135
          • Serotype Y
        • U.K. Sales Outlook (Revenue, USD Million; 2018 - 2030)
          • Private
          • Public
      • Germany
        • Germany Type Outlook (Revenue, USD Million; 2018 - 2030)
          • Bivalent
          • Quadrivalent
          • Others
        • Germany Brand Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Menactra
          • Menveo
          • Nimenrix
          • Trumenba
          • Bexsero
          • Others
        • Germany Age Group Outlook (Revenue, USD Million; 2018 - 2030)
          • Infants (0 to 2 years)
          • Children and Adults (2 years & above)
        • Germany Serotype Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Serotype A
          • Serotype B
          • Serotype C
          • Serotype W-135
          • Serotype Y
        • Germany Sales Channel Outlook (Revenue, USD Million; 2018 - 2030)
          • Private
          • Public
      • France
        • France Type Outlook (Revenue, USD Million; 2018 - 2030)
          • Bivalent
          • Quadrivalent
          • Others
        • France Brand Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Menactra
          • Menveo
          • Nimenrix
          • Trumenba
          • Bexsero
          • Others
        • France Age Group Outlook (Revenue, USD Million; 2018 - 2030)
          • Infants (0 to 2 years)
          • Children and Adults (2 years & above)
        • France Serotype Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Serotype A
          • Serotype B
          • Serotype C
          • Serotype W-135
          • Serotype Y
        • France Sales Channel Outlook (Revenue, USD Million; 2018 - 2030)
          • Private
          • Public
      •  Russia
        • Russia Type Outlook (Revenue, USD Million; 2018 - 2030)
          • Bivalent
          • Quadrivalent
          • Others
        • Russia Brand Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Menactra
          • Menveo
          • Nimenrix
          • Trumenba
          • Bexsero
          • Others
        • Russia Age Group Outlook (Revenue, USD Million; 2018 - 2030)
          • Infants (0 to 2 years)
          • Children and Adults (2 years & above)
        • Russia Serotype Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Serotype A
          • Serotype B
          • Serotype C
          • Serotype W-135
          • Serotype Y
        • Russia Sales Channel Outlook (Revenue, USD Million; 2018 - 2030)
          • Private
          • Public
      •  Spain
        • Spain Type Outlook (Revenue, USD Million; 2018 - 2030)
          • Bivalent
          • Quadrivalent
          • Others
        • Spain Band Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Menactra
          • Menveo
          • Nimenrix
          • Trumenba
          • Bexsero
          • Others
        • Spain Age Group Outlook (Revenue, USD Million; 2018 - 2030)
          • Infants (0 to 2 years)
          • Children and Adults (2 years & above)
        • Spain Serotype Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Serotype A
          • Serotype B
          • Serotype C
          • Serotype W-135
          • Serotype Y
        • Spain Sales Channel Outlook (Revenue, USD Million; 2018 - 2030)
          • Private
          • Public
      •  Italy
        • Italy Type Outlook (Revenue, USD Million; 2018 - 2030)
          • Bivalent
          • Quadrivalent
          • Others
        • Italy Brand Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Menactra
          • Menveo
          • Nimenrix
          • Trumenba
          • Bexsero
          • Others
        • Italy Age Group Outlook (Revenue, USD Million; 2018 - 2030)
          • Infants (0 to 2 years)
          • Children and Adults (2 years & above)
        • Italy Serotype Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Serotype A
          • Serotype B
          • Serotype C
          • Serotype W-135
          • Serotype Y
        • Italy Sales Channel Outlook (Revenue, USD Million; 2018 - 2030)
          • Private
          • Public
      • Belarus
        • Belarus Type Outlook (Revenue, USD Million; 2018 - 2030)
          • Bivalent
          • Quadrivalent
          • Others
        • Belarus Brand Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Menactra
          • Menveo
          • Nimenrix
          • Trumenba
          • Bexsero
          • Others
        • Belarus Age Group Outlook (Revenue, USD Million; 2018 - 2030)
          • Infants (0 to 2 years)
          • Children and Adults (2 years & above)
        • Belarus Serotype Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Serotype A
          • Serotype B
          • Serotype C
          • Serotype W-135
          • Serotype Y
        • Belarus Sales Outlook (Revenue, USD Million; 2018 - 2030)
          • Private
          • Public
      •  Georgia
        • Georgia Type Outlook (Revenue, USD Million; 2018 - 2030)
          • Bivalent
          • Quadrivalent
          • Others
        • Georgia Brand Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Menactra
          • Menveo
          • Nimenrix
          • Trumenba
          • Bexsero
          • Others
        • Georgia Age Group Outlook (Revenue, USD Million; 2018 - 2030)
          • Infants (0 to 2 years)
          • Children and Adults (2 years & above)
        • Georgia Serotype Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Serotype A
          • Serotype B
          • Serotype C
          • Serotype W-135
          • Serotype Y
        • Georgia Sales Outlook (Revenue, USD Million; 2018 - 2030)
          • Private
          • Public
      •  Moldova
        • Moldova Type Outlook (Revenue, USD Million; 2018 - 2030)
          • Bivalent
          • Quadrivalent
          • Others
        • Moldova Brand Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Menactra
          • Menveo
          • Nimenrix
          • Trumenba
          • Bexsero
          • Others
        • Moldova Age Group Outlook (Revenue, USD Million; 2018 - 2030)
          • Infants (0 to 2 years)
          • Children and Adults (2 years & above)
        • Moldova Serotype Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Serotype A
          • Serotype B
          • Serotype C
          • Serotype W-135
          • Serotype Y
        • Moldova Sales Outlook (Revenue, USD Million; 2018 - 2030)
          • Private
          • Public
      • Denmark
        • Denmark Type Outlook (Revenue, USD Million; 2018 - 2030)
          • Bivalent
          • Quadrivalent
          • Others
        • Denmark Brand Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Menactra
          • Menveo
          • Nimenrix
          • Trumenba
          • Bexsero
          • Others
        • Denmark Age Group Outlook (Revenue, USD Million; 2018 - 2030)
          • Infants (0 to 2 years)
          • Children and Adults (2 years & above)
        • Denmark Serotype Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Serotype A
          • Serotype B
          • Serotype C
          • Serotype W-135
          • Serotype Y
        • Denmark Sales Channel Outlook (Revenue, USD Million; 2018 - 2030)
          • Private
          • Public
      • Sweden
        • Sweden Type Outlook (Revenue, USD Million; 2018 - 2030)
          • Bivalent
          • Quadrivalent
          • Others
        • Sweden Brand Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Menactra
          • Menveo
          • Nimenrix
          • Trumenba
          • Bexsero
          • Others
        • Sweden Age Group Outlook (Revenue, USD Million; 2018 - 2030)
          • Infants (0 to 2 years)
          • Children and Adults (2 years & above)
        • Sweden Serotype Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Serotype A
          • Serotype B
          • Serotype C
          • Serotype W-135
          • Serotype Y
        • Sweden Sales Channel Outlook (Revenue, USD Million; 2018 - 2030)
          • Private
          • Public
      • Norway
        • Norway Type Outlook (Revenue, USD Million; 2018 - 2030)
          • Bivalent
          • Quadrivalent
          • Others
        • Norway Brand Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Menactra
          • Menveo
          • Nimenrix
          • Trumenba
          • Bexsero
          • Others
        • Norway Age Group Outlook (Revenue, USD Million; 2018 - 2030)
          • Infants (0 to 2 years)
          • Children and Adults (2 years & above)
        • Norway Serotype Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Serotype A
          • Serotype B
          • Serotype C
          • Serotype W-135
          • Serotype Y
        • Norway Sales Channel Outlook (Revenue, USD Million; 2018 - 2030)
          • Private
          • Public
    • Asia Pacific
      • Asia Pacific Type Outlook (Revenue, USD Million; 2018 - 2030)
        • Bivalent
        • Quadrivalent
        • Others
      • Asia Pacific Brand Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
        • Menactra
        • Menveo
        • Nimenrix
        • Trumenba
        • Bexsero
        • Others
      • Asia Pacific Age Group Outlook (Revenue, USD Million; 2018 - 2030)
        • Infants (0 to 2 years)
        • Children and Adults (2 years & above)
      • Asia Pacific Serotype Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
        • Serotype A
        • Serotype B
        • Serotype C
        • Serotype W-135
        • Serotype Y
      • Asia Pacific Sales Outlook (Revenue, USD Million; 2018 - 2030)
        • Private
        • Public
      • Japan
        • Japan Type Outlook (Revenue, USD Million; 2018 - 2030)
          • Bivalent
          • Quadrivalent
          • Others
        • Japan Brand Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Menactra
          • Menveo
          • Nimenrix
          • Trumenba
          • Bexsero
          • Others
        • Japan Age Group Outlook (Revenue, USD Million; 2018 - 2030)
          • Infants (0 to 2 years)
          • Children and Adults (2 years & above)
        • Japan Serotype Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Serotype A
          • Serotype B
          • Serotype C
          • Serotype W-135
          • Serotype Y
        • Japan Sales Outlook (Revenue, USD Million; 2018 - 2030)
          • Private
          • Public
      • China
        • China Type Outlook (Revenue, USD Million; 2018 - 2030)
          • Bivalent
          • Quadrivalent
          • Others
        • China Brand Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Menactra
          • Menveo
          • Nimenrix
          • Trumenba
          • Bexsero
          • Others
        • China Age Group Outlook (Revenue, USD Million; 2018 - 2030)
          • Infants (0 to 2 years)
          • Children and Adults (2 years & above)
        • China Serotype Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Serotype A
          • Serotype B
          • Serotype C
          • Serotype W-135
          • Serotype Y
        • China Sales Outlook (Revenue, USD Million; 2018 - 2030)
          • Private
          • Public
      • India
        • India Type Outlook (Revenue, USD Million; 2018 - 2030)
          • Bivalent
          • Quadrivalent
          • Others
        • India Brand Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Menactra
          • Menveo
          • Nimenrix
          • Trumenba
          • Bexsero
          • Others
        • India Age Group Outlook (Revenue, USD Million; 2018 - 2030)
          • Infants (0 to 2 years)
          • Children and Adults (2 years & above)
        • India Serotype Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Serotype A
          • Serotype B
          • Serotype C
          • Serotype W-135
          • Serotype Y
        • India Sales Outlook (Revenue, USD Million; 2018 - 2030)
          • Private
          • Public
      • South Korea
        • South Korea Type Outlook (Revenue, USD Million; 2018 - 2030)
          • Bivalent
          • Quadrivalent
          • Others
        • South Korea Brand Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Menactra
          • Menveo
          • Nimenrix
          • Trumenba
          • Bexsero
          • Others
        • South Korea Age Group Outlook (Revenue, USD Million; 2018 - 2030)
          • Infants (0 to 2 years)
          • Children and Adults (2 years & above)
        • South Korea Serotype Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Serotype A
          • Serotype B
          • Serotype C
          • Serotype W-135
          • Serotype Y
        • South Korea Sales Outlook (Revenue, USD Million; 2018 - 2030)
          • Private
          • Public
      • Australia
        • Australia Type Outlook (Revenue, USD Million; 2018 - 2030)
          • Bivalent
          • Quadrivalent
          • Others
        • Australia Brand Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Menactra
          • Menveo
          • Nimenrix
          • Trumenba
          • Bexsero
          • Others
        • Australia Age Group Outlook (Revenue, USD Million; 2018 - 2030)
          • Infants (0 to 2 years)
          • Children and Adults (2 years & above)
        • Australia Serotype Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Serotype A
          • Serotype B
          • Serotype C
          • Serotype W-135
          • Serotype Y
        • Australia Sales Outlook (Revenue, USD Million; 2018 - 2030)
          • Private
          • Public
      • Singapore
        • Singapore Type Outlook (Revenue, USD Million; 2018 - 2030)
          • Bivalent
          • Quadrivalent
          • Others
        • Singapore Brand Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Menactra
          • Menveo
          • Nimenrix
          • Trumenba
          • Bexsero
          • Others
        • Singapore Age Group Outlook (Revenue, USD Million; 2018 - 2030)
          • Infants (0 to 2 years)
          • Children and Adults (2 years & above)
        • Singapore Serotype Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Serotype A
          • Serotype B
          • Serotype C
          • Serotype W-135
          • Serotype Y
        • Singapore Sales Outlook (Revenue, USD Million; 2018 - 2030)
          • Private
          • Public
      • Thailand
        • Thailand Type Outlook (Revenue, USD Million; 2018 - 2030)
          • Bivalent
          • Quadrivalent
          • Others
        • Thailand Brand Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Menactra
          • Menveo
          • Nimenrix
          • Trumenba
          • Bexsero
          • Others
        • Thailand Age Group Outlook (Revenue, USD Million; 2018 - 2030)
          • Infants (0 to 2 years)
          • Children and Adults (2 years & above)
        • Thailand Serotype Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Serotype A
          • Serotype B
          • Serotype C
          • Serotype W-135
          • Serotype Y
        • Thailand Sales Outlook (Revenue, USD Million; 2018 - 2030)
          • Private
          • Public
      • Vietnam
        • Vietnam Type Outlook (Revenue, USD Million; 2018 - 2030)
          • Bivalent
          • Quadrivalent
          • Others
        • Vietnam Brand Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Menactra
          • Menveo
          • Nimenrix
          • Trumenba
          • Bexsero
          • Others
        • Vietnam Age Group Outlook (Revenue, USD Million; 2018 - 2030)
          • Infants (0 to 2 years)
          • Children and Adults (2 years & above)
        • Vietnam Serotype Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Serotype A
          • Serotype B
          • Serotype C
          • Serotype W-135
          • Serotype Y
        • Vietnam Sales Outlook (Revenue, USD Million; 2018 - 2030)
          • Private
          • Public
      • Malaysia
        • Malaysia Type Outlook (Revenue, USD Million; 2018 - 2030)
          • Bivalent
          • Quadrivalent
          • Others
        • Malaysia Brand Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Menactra
          • Menveo
          • Nimenrix
          • Trumenba
          • Bexsero
          • Others
        • Malaysia Age Group Outlook (Revenue, USD Million; 2018 - 2030)
          • Infants (0 to 2 years)
          • Children and Adults (2 years & above)
        • Malaysia Serotype Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Serotype A
          • Serotype B
          • Serotype C
          • Serotype W-135
          • Serotype Y
        • Malaysia Sales Outlook (Revenue, USD Million; 2018 - 2030)
          • Private
          • Public
      • Indonesia
        • Indonesia Type Outlook (Revenue, USD Million; 2018 - 2030)
          • Bivalent
          • Quadrivalent
          • Others
        • Indonesia Brand Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Menactra
          • Menveo
          • Nimenrix
          • Trumenba
          • Bexsero
          • Others
        • Indonesia Age Group Outlook (Revenue, USD Million; 2018 - 2030)
          • Infants (0 to 2 years)
          • Children and Adults (2 years & above)
        • Indonesia Serotype Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Serotype A
          • Serotype B
          • Serotype C
          • Serotype W-135
          • Serotype Y
        • Indonesia Sales Outlook (Revenue, USD Million; 2018 - 2030)
          • Private
          • Public
      • Kazakhstan
        • Kazakhstan Type Outlook (Revenue, USD Million; 2018 - 2030)
          • Bivalent
          • Quadrivalent
          • Others
        • Kazakhstan Brand Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Menactra
          • Menveo
          • Nimenrix
          • Trumenba
          • Bexsero
          • Others
        • Kazakhstan Age Group Outlook (Revenue, USD Million; 2018 - 2030)
          • Infants (0 to 2 years)
          • Children and Adults (2 years & above)
        • Kazakhstan Serotype Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Serotype A
          • Serotype B
          • Serotype C
          • Serotype W-135
          • Serotype Y
        • Kazakhstan Sales Outlook (Revenue, USD Million; 2018 - 2030)
          • Private
          • Public
      • Kyrgyzstan
        • Kyrgyzstan Type Outlook (Revenue, USD Million; 2018 - 2030)
          • Bivalent
          • Quadrivalent
          • Others
        • Kyrgyzstan Brand Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Menactra
          • Menveo
          • Nimenrix
          • Trumenba
          • Bexsero
          • Others
        • Kyrgyzstan Age Group Outlook (Revenue, USD Million; 2018 - 2030)
          • Infants (0 to 2 years)
          • Children and Adults (2 years & above)
        • Kyrgyzstan Serotype Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Serotype A
          • Serotype B
          • Serotype C
          • Serotype W-135
          • Serotype Y
        • Kyrgyzstan Sales Outlook (Revenue, USD Million; 2018 - 2030)
          • Private
          • Public
      • Armenia
        • Armenia Type Outlook (Revenue, USD Million; 2018 - 2030)
          • Bivalent
          • Quadrivalent
          • Others
        • Armenia Brand Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Menactra
          • Menveo
          • Nimenrix
          • Trumenba
          • Bexsero
          • Others
        • Armenia Age Group Outlook (Revenue, USD Million; 2018 - 2030)
          • Infants (0 to 2 years)
          • Children and Adults (2 years & above)
        • Armenia Serotype Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Serotype A
          • Serotype B
          • Serotype C
          • Serotype W-135
          • Serotype Y
        • Armenia Sales Outlook (Revenue, USD Million; 2018 - 2030)
          • Private
          • Public
      • Azerbaijan
        • Azerbaijan Type Outlook (Revenue, USD Million; 2018 - 2030)
          • Bivalent
          • Quadrivalent
          • Others
        • Azerbaijan Brand Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Menactra
          • Menveo
          • Nimenrix
          • Trumenba
          • Bexsero
          • Others
        • Azerbaijan Age Group Outlook (Revenue, USD Million; 2018 - 2030)
          • Infants (0 to 2 years)
          • Children and Adults (2 years & above)
        • Azerbaijan Serotype Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Serotype A
          • Serotype B
          • Serotype C
          • Serotype W-135
          • Serotype Y
        • Azerbaijan Sales Outlook (Revenue, USD Million; 2018 - 2030)
          • Private
          • Public
      • Tajikistan
        • Tajikistan Type Outlook (Revenue, USD Million; 2018 - 2030)
          • Bivalent
          • Quadrivalent
          • Others
        • Tajikistan Brand Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Menactra
          • Menveo
          • Nimenrix
          • Trumenba
          • Bexsero
          • Others
        • Tajikistan Age Group Outlook (Revenue, USD Million; 2018 - 2030)
          • Infants (0 to 2 years)
          • Children and Adults (2 years & above)
        • Tajikistan Serotype Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Serotype A
          • Serotype B
          • Serotype C
          • Serotype W-135
          • Serotype Y
        • Tajikistan Sales Outlook (Revenue, USD Million; 2018 - 2030)
          • Private
          • Public
      • Turkmenistan
        • Turkmenistan Type Outlook (Revenue, USD Million; 2018 - 2030)
          • Bivalent
          • Quadrivalent
          • Others
        • Turkmenistan Brand Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Menactra
          • Menveo
          • Nimenrix
          • Trumenba
          • Bexsero
          • Others
        • Turkmenistan Age Group Outlook (Revenue, USD Million; 2018 - 2030)
          • Infants (0 to 2 years)
          • Children and Adults (2 years & above)
        • Turkmenistan Serotype Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Serotype A
          • Serotype B
          • Serotype C
          • Serotype W-135
          • Serotype Y
        • Turkmenistan Sales Outlook (Revenue, USD Million; 2018 - 2030)
          • Private
          • Public
      • Uzbekistan
        • Uzbekistan Type Outlook (Revenue, USD Million; 2018 - 2030)
          • Bivalent
          • Quadrivalent
          • Others
        • Uzbekistan Brand Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Menactra
          • Menveo
          • Nimenrix
          • Trumenba
          • Bexsero
          • Others
        • Uzbekistan Age Group Outlook (Revenue, USD Million; 2018 - 2030)
          • Infants (0 to 2 years)
          • Children and Adults (2 years & above)
        • Uzbekistan Serotype Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Serotype A
          • Serotype B
          • Serotype C
          • Serotype W-135
          • Serotype Y
        • Uzbekistan Sales Outlook (Revenue, USD Million; 2018 - 2030)
          • Private
          • Public
    • Latin America
      • Latin America Type Outlook (Revenue, USD Million; 2018 - 2030)
        • Bivalent
        • Quadrivalent
        • Others
      • Latin America Brand Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
        • Menactra
        • Nimenrix
        • Menveo
        • Trumenba
        • Bexsero
        • Others
      • Latin America Age Group Outlook (Revenue, USD Million; 2018 - 2030)
        • Infants (0 to 2 years)
        • Children and Adults (2 years & above)
        • Latin America Serotype Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
        • Serotype A
        • Serotype B
        • Serotype C
        • Serotype W-135
        • Serotype Y
      • Latin America Sales Outlook (Revenue, USD Million; 2018 - 2030)
        • Private
        • Public
      • Brazil
        • Brazil Type Outlook (Revenue, USD Million; 2018 - 2030)
          • Bivalent
          • Quadrivalent
          • Others
        • Brazil Brand Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Menactra
          • Menveo
          • Trumenba
          • Bexsero
          • Others
        • Brazil Age Group Outlook (Revenue, USD Million; 2018 - 2030)
          • Infants (0 to 2 years)
          • Children and Adults (2 years & above)
        • Brazil Serotype Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Serotype A
          • Serotype B
          • Serotype C
          • Serotype W-135
          • Serotype Y
        • Brazil Sales Outlook (Revenue, USD Million; 2018 - 2030)
          • Private
          • Public
      • Mexico
        • Mexico Type Outlook (Revenue, USD Million; 2018 - 2030)
          • Bivalent
          • Quadrivalent
          • Others
        • Mexico Brand Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Menactra
          • Menveo
          • Nimenrix
          • Trumenba
          • Bexsero
          • Others
        • Mexico Age Group Outlook (Revenue, USD Million; 2018 - 2030)
          • Infants (0 to 2 years)
          • Children and Adults (2 years & above)
        • Mexico Serotype Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Serotype A
          • Serotype B
          • Serotype C
          • Serotype W-135
          • Serotype Y
        • Mexico Sales Outlook (Revenue, USD Million; 2018 - 2030)
          • Private
          • Public
      • Argentina
        • Argentina Type Outlook (Revenue, USD Million; 2018 - 2030)
          •  Bivalent
          •  Quadrivalent
          • Others
        • Argentina Brand Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Menactra
          • Menveo
          • Nimenrix
          • Trumenba
          • Bexsero
          • Others
        • Argentina Age Group Outlook (Revenue, USD Million; 2018 - 2030)
          • Infants (0 to 2 years)
          • Children and Adults (2 years & above)
        • Argentina Serotype Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Serotype A
          • Serotype B
          • Serotype C
          • Serotype W-135
          • Serotype Y
        • Argentina Sales Outlook (Revenue, USD Million; 2018 - 2030)
          • Private
          • Public
      • Chile
        • Chile Type Outlook (Revenue, USD Million; 2018 - 2030)
          •  Bivalent
          • Quadrivalent
          • Others
        • Chile Brand Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Menactra
          • Menveo
          • Nimenrix
          • Trumenba
          • Bexsero
          • Others
        • Chile Age Group Outlook (Revenue, USD Million; 2018 - 2030)
          • Infants (0 to 2 years)
          • Children and Adults (2 years & above)
        • Chile Serotype Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Serotype A
          • Serotype B
          • Serotype C
          • Serotype W-135
          • Serotype Y
        • Chile Sales Outlook (Revenue, USD Million; 2018 - 2030)
          • Private
          • Public
      • Cuba
        • Cuba Type Outlook (Revenue, USD Million; 2018 - 2030)
          • Bivalent
          • Quadrivalent
          • Others
        • Cuba Brand Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Menactra
          • Menveo
          • Nimenrix
          • Trumenba
          • Bexsero
          • Others
        • Cuba Age Group Outlook (Revenue, USD Million; 2018 - 2030)
          • Infants (0 to 2 years)
          • Children and Adults (2 years & above)
        • Cuba Serotype Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Serotype A
          • Serotype B
          • Serotype C
          • Serotype W-135
          • Serotype Y
        • Cuba Sales Outlook (Revenue, USD Million; 2018 - 2030)
          • Private
          • Public
      • Ecuador
        • Ecuador Type Outlook (Revenue, USD Million; 2018 - 2030)
          • Bivalent
          • Quadrivalent
          • Others
        • Ecuador Brand Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Menactra
          • Menveo
          • Nimenrix
          • Trumenba
          • Bexsero
          • Others
        • Ecuador Age Group Outlook (Revenue, USD Million; 2018 - 2030)
          • Infants (0 to 2 years)
          • Children and Adults (2 years & above)
        • Ecuador Serotype Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Serotype A
          • Serotype B
          • Serotype C
          • Serotype W-135
          • Serotype Y
        • Ecuador Sales Outlook (Revenue, USD Million; 2018 - 2030)
          • Private
          • Public
      • Peru
        • Peru Type Outlook (Revenue, USD Million; 2018 - 2030)
          • Bivalent
          • Quadrivalent
          • Others
        • Peru Brand Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Menactra
          • Menveo
          • Nimenrix
          • Trumenba
          • Bexsero
          • Others
        • Peru Age Group Outlook (Revenue, USD Million; 2018 - 2030)
          • Infants (0 to 2 years)
          • Children and Adults (2 years & above)
        • Peru Serotype Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Serotype A
          • Serotype B
          • Serotype C
          • Serotype W-135
          • Serotype Y
        • Peru Sales Outlook (Revenue, USD Million; 2018 - 2030)
          • Private
          • Public
      • Colombia
        • Colombia Type Outlook (Revenue, USD Million; 2018 - 2030)
          • Bivalent
          • Quadrivalent
          • Others
        • Colombia Brand Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Menactra
          • Menveo
          • Nimenrix
          • Trumenba
          • Bexsero
          • Others
        • Colombia Age Group Outlook (Revenue, USD Million; 2018 - 2030)
          • Infants (0 to 2 years)
          • Children and Adults (2 years & above)
        • Colombia Serotype Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Serotype A
          • Serotype B
          • Serotype C
          • Serotype W-135
          • Serotype Y
        • Colombia Sales Outlook (Revenue, USD Million; 2018 - 2030)
          • Private
          • Public
      • Venezuela
        • Venezuela Type Outlook (Revenue, USD Million; 2018 - 2030)
          • Bivalent
          • Quadrivalent
          • Others
        • Venezuela Brand Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Menactra
          • Menveo
          • Nimenrix
          • Trumenba
          • Bexsero
          • Others
        • Venezuela Age Group Outlook (Revenue, USD Million; 2018 - 2030)
          • Infants (0 to 2 years)
          • Children and Adults (2 years & above)
        • Venezuela Serotype Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Serotype A
          • Serotype B
          • Serotype C
          • Serotype W-135
          • Serotype Y
        • Venezuela Sales Outlook (Revenue, USD Million; 2018 - 2030)
          • Private
          • Public
    • Middle East and Africa
      • Middle East and Africa Type Outlook (Revenue, USD Million; 2018 - 2030)
        • Bivalent
        • Quadrivalent
        • Others
      • Middle East and Africa Brand Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
        • Menactra
        • Menveo
        • Nimenrix
        • Trumenba
        • Bexsero
        • Others
      • Middle East and Africa Age Group Outlook (Revenue, USD Million; 2018 - 2030)
        • Infants (0 to 2 years)
        • Children and Adults (2 years & above)
      • Middle East and Africa Serotype Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
        • Serotype A
        • Serotype B
        • Serotype C
        • Serotype W-135
        • Serotype Y
      • Middle East and Africa Sales Outlook (Revenue, USD Million; 2018 - 2030)
        • Private
        • Public
      • South Africa
        • South Africa Type Outlook (Revenue, USD Million; 2018 - 2030)
          • Bivalent
          • Quadrivalent
          • Others
        • South Africa Brand Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Menactra
          • Menveo
          • Nimenrix
          • Trumenba
          • Bexsero
          • Others
        • South Africa Age Group Outlook (Revenue, USD Million; 2018 - 2030)
          • Infants (0 to 2 years)
          • Children and Adults (2 years & above)
        • South Africa Serotype Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Serotype A
          • Serotype B
          • Serotype C
          • Serotype W-135
          • Serotype Y
        • South Africa Sales Outlook (Revenue, USD Million; 2018 - 2030)
          • Private
          • Public
      • Saudi Arabia
        • Saudi Arabia Type Outlook (Revenue, USD Million; 2018 - 2030)
          • Bivalent
          • Quadrivalent
          • Others
        • Saudi Arabia Brand Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Menactra
          • Menveo
          • Nimenrix
          • Trumenba
          • Bexsero
          • Others
        • Saudi Arabia Age Group Outlook (Revenue, USD Million; 2018 - 2030)
          • Infants (0 to 2 years)
          • Children and Adults (2 years & above)
        • Saudi Arabia Serotype Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Serotype A
          • Serotype B
          • Serotype C
          • Serotype W-135
          • Serotype Y
        • Saudi Arabia Sales Outlook (Revenue, USD Million; 2018 - 2030)
          • Private
          • Public
      • UAE
        • UAE Type Outlook (Revenue, USD Million; 2018 - 2030)
          • Bivalent
          • Quadrivalent
          • Others
        • UAE Brand Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Menactra
          • Menveo
          • Nimenrix
          • Trumenba
          • Bexsero
          • Others
        • UAE Age Group Outlook (Revenue, USD Million; 2018 - 2030)
          • Infants (0 to 2 years)
          • Children and Adults (2 years & above)
        • UAE Serotype Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Serotype A
          • Serotype B
          • Serotype C
          • Serotype W-135
          • Serotype Y
        • UAE Sales Outlook (Revenue, USD Million; 2018 - 2030)
          • Private
          • Public
      • Algeria
        • Algeria Type Outlook (Revenue, USD Million; 2018 - 2030)
          • Bivalent
          • Quadrivalent
          • Others
        • Algeria Brand Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Menactra
          • Menveo
          • Nimenrix
          • Trumenba
          • Bexsero
          • Others
        • Algeria Age Group Outlook (Revenue, USD Million; 2018 - 2030)
          • Infants (0 to 2 years)
          • Children and Adults (2 years & above)
        • Algeria Serotype Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Serotype A
          • Serotype B
          • Serotype C
          • Serotype W-135
          • Serotype Y
        • Algeria Sales Outlook (Revenue, USD Million; 2018 - 2030)
          • Private
          • Public
      • Egypt
        • Egypt Type Outlook (Revenue, USD Million; 2018 - 2030)
          • Bivalent
          • Quadrivalent
          • Others
        • Egypt Brand Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Menactra
          • Menveo
          • Nimenrix
          • Trumenba
          • Bexsero
          • Others
        • Egypt Age Group Outlook (Revenue, USD Million; 2018 - 2030)
          • Infants (0 to 2 years)
          • Children and Adults (2 years & above)
        • Egypt Serotype Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Serotype A
          • Serotype B
          • Serotype C
          • Serotype W-135
          • Serotype Y
        • Egypt Sales Outlook (Revenue, USD Million; 2018 - 2030)
          • Private
          • Public
      • Tunisia
        • Tunisia Type Outlook (Revenue, USD Million; 2018 - 2030)
          • Bivalent
          • Quadrivalent
          • Others
        • Tunisia Brand Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Menactra
          • Menveo
          • Nimenrix
          • Trumenba
          • Bexsero
          • Others
        • Tunisia Age Group Outlook (Revenue, USD Million; 2018 - 2030)
          • Infants (0 to 2 years)
          • Children and Adults (2 years & above)
        • Tunisia Serotype Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Serotype A
          • Serotype B
          • Serotype C
          • Serotype W-135
          • Serotype Y
        • Tunisia Sales Outlook (Revenue, USD Million; 2018 - 2030)
          • Private
          • Public
      • Iran
        • Iran Type Outlook (Revenue, USD Million; 2018 - 2030)
          • Bivalent
          • Quadrivalent
          • Others
        • Iran Brand Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Menactra
          • Menveo
          • Nimenrix
          • Trumenba
          • Bexsero
          • Others
        • Iran Age Group Outlook (Revenue, USD Million; 2018 - 2030)
          • Infants (0 to 2 years)
          • Children and Adults (2 years & above)
        • Iran Serotype Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Serotype A
          • Serotype B
          • Serotype C
          • Serotype W-135
          • Serotype Y
        • Iran Sales Outlook (Revenue, USD Million; 2018 - 2030)
          • Private
          • Public
      • Turkey
        • Turkey Type Outlook (Revenue, USD Million; 2018 - 2030)
          • Bivalent
          • Quadrivalent
          • Others
        • Turkey Brand Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Menactra
          • Menveo
          • Nimenrix
          • Trumenba
          • Bexsero
          • Others
        • Turkey Age Group Outlook (Revenue, USD Million; 2018 - 2030)
          • Infants (0 to 2 years)
          • Children and Adults (2 years & above)
          • Turkey Serotype Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Serotype A
          • Serotype B
          • Serotype C
          • Serotype W-135
          • Serotype Y
        • Turkey Sales Outlook (Revenue, USD Million; 2018 - 2030)
          • Private
          • Public
      • Iraq
        • Iraq Type Outlook (Revenue, USD Million; 2018 - 2030)
          • Bivalent
          • Quadrivalent
          • Others
        • Iraq Brand Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Menactra
          • Menveo
          • Nimenrix
          • Trumenba
          • Bexsero
          • Others
        • Iraq Age Group Outlook (Revenue, USD Million; 2018 - 2030)
          • Infants (0 to 2 years)
          • Children and Adults (2 years & above)
        • Iraq Serotype Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Serotype A
          • Serotype B
          • Serotype C
          • Serotype W-135
          • Serotype Y
        • Iraq Sales Outlook (Revenue, USD Million; 2018 - 2030)
          • Private
          • Public
      • Morocco
        • Morocco Type Outlook (Revenue, USD Million; 2018 - 2030)
          • Bivalent
          • Quadrivalent
          • Others
        • Morocco Brand Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Menactra
          • Menveo
          • Nimenrix
          • Trumenba
          • Bexsero
          • Others
        • Morocco Age Group Outlook (Revenue, USD Million; 2018 - 2030)
          • Infants (0 to 2 years)
          • Children and Adults (2 years & above)
        • Morocco Serotype Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Serotype A
          • Serotype B
          • Serotype C
          • Serotype W-135
          • Serotype Y
        • Morocco Sales Outlook (Revenue, USD Million; 2018 - 2030)
          • Private
          • Public
      • Kuwait
        • Kuwait Type Outlook (Revenue, USD Million; 2018 - 2030)
          • Bivalent
          • Quadrivalent
          • Others
        • Kuwait Brand Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Menactra
          • Menveo
          • Nimenrix
          • Trumenba
          • Bexsero
          • Others
        • Kuwait Age Group Outlook (Revenue, USD Million; 2018 - 2030)
          • Infants (0 to 2 years)
          • Children and Adults (2 years & above)
        • Kuwait Serotype Outlook (Revenue, USD Million; 2018 - 2030) (Volume, Number of Doses (in Thousands)
          • Serotype A
          • Serotype B
          • Serotype C
          • Serotype W-135
          • Serotype Y
        • Kuwait Sales Channel Outlook (Revenue, USD Million; 2018 - 2030)
          • Private
          • Public

Meningococcal Vaccines Market Dynamics

Driver: Rising R&D initiatives in the meningococcal vaccine space

Vaccine candidates in phase III clinical trials are anticipated to be launched in the coming years. For instance, in June 2020, Pfizer, Inc. initiated phase III clinical trials on NCT04440163/PF-06886992, which is a pentavalent meningococcal vaccine candidate (MenABCWY). Safety, immunogenicity, and tolerability are assessed & compared with licensed meningococcal vaccines in adolescents and young adults. Moreover, there are non-profit organizations that invest & fund various research projects on meningitis. In June 2021, Sanofi announced an investment of USD 453 million in an mRNA vaccines Center for Excellence. This investment may leverage the increased capacity of research to address the demand for new vaccines, including meningococcal. Furthermore, the Meningitis Research Foundation funds different research projects related to the prevention of meningitis. Therefore, increasing investment and funding for research is anticipated to boost R&D for the development of meningococcal vaccines, impelling market growth.

Driver: Growing prevalence of meningitis globally

The rising prevalence of meningococcal disease is expected to be a key impact-rendering driver. According to the CDC, around 1.2 million cases of bacterial meningitis are projected to occur globally every year. The highest burden of meningitis was observed in sub-Saharan Africa and approximately 30,000 cases are reported annually in this region. Furthermore, according to ECDC, it was estimated that in 2017, 3,221 confirmed cases were observed in EU member states, wherein 58% of cases were found in the UK, France, Spain, and Germany. The number of invasive meningococcal disease cases in the UK stood at 525 cases per 100,000 from 2018 to 2019. Globally, the incidence of meningitis is highest due to N. meningitidis in the meningitis belt, which includes regions of sub-Saharan Africa. According to the CDC, the incidence rate in sub-Saharan Africa is 10 to 100 cases per 100,000 people. In the U.S., around 600 to 1,000 people suffer from meningitis, and 10 to 15% die due to this disease every year.

Restraint: High costs incurred in vaccine storage and supply

High costs associated with storing vaccines in bulk due to the need to maintain sufficient supply are anticipated to impede the meningococcal vaccine market growth. It is one of the biggest challenges faced by distribution systems of vaccines and significantly impacts immunization programs. This overstocking raises cold storage costs, resulting in vaccine wastage. The wastage rate is approximately 60 to 70%. However, new vaccines that cost several dollars per dose are being introduced, which reduces costs associated with storage and wastage. In addition, vaccines can be kept at 45°C for 6 months, and it is required to be kept between 2°C and 8°C. Therefore, some vaccines need to be moved from the cold chain to a temperature-controlled chain that is 25°C, which is expected to enable countries to cut storage costs.

What Does This Report Include?

This section will provide insights into the contents included in this meningococcal vaccines market report and help gain clarity on the structure of the report to assist readers in navigating smoothly.

Meningococcal vaccines market qualitative analysis

  • Industry overview

  • Industry trends

  • Market drivers and restraints

  • Market size

  • Growth prospects

  • Porter’s analysis

  • PESTEL analysis

  • Key market opportunities prioritized

  • Competitive landscape

    • Company overview

    • Financial performance

    • Product benchmarking

    • Latest strategic developments

Meningococcal vaccines market quantitative analysis

  • Market size, estimates, and forecast from 2018 to 2030

  • Market estimates and forecast for product segments up to 2030

  • Regional market size and forecast for product segments up to 2030

  • Market estimates and forecast for application segments up to 2030

  • Regional market size and forecast for application segments up to 2030

  • Company financial performance

What questions do you have? Get quick response from our industry experts. Request a Free Consultation
pdf

GET A FREE SAMPLE

bck

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

cog

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

esomar icon

ESOMAR certified & member

ISO

ISO Certified

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.

great place to work icon